September 22, 2022
In early September 2022, Cryoport announced its strategic partnership with BioLife Plasma Services, whos parent company is the global biopharmaceutical company Takeda. Together, the two companies are...
July 01, 2022
The recent partnership between Cell Matters and Cryoport has proven to be extremely beneficial in addressing a critical step in cell and gene therapy research and commercialization, reducing risks...
June 30, 2022
Cryoport Systems' first two Global Supply Chain Centers in Morris Plains, New Jersey and Houston, Texas will provide critical support to major biotech companies around the world as well as play a...
April 27, 2022
The recent acquisition of of Cell&Co BioServices by Cryoport, Inc. will help to expand global service offerings by generating opportunities for clinical trial and cell and gene therapy developers in...
April 23, 2022
Cryoport Systems' new Global Supply Chain Center, location in Houston, Texas, will service the massive life sciences research sector in the Houston metropolitan area and expand its local presence....
February 02, 2022
To better deliver end-to-end cryopreservation services for leukapheresis derived therapies, Cryoport has strategically partnered with Cell Matters, S.A. In late January, Contract Pharma articulates...
December 01, 2021
By Mintoi Chessa-Florea in London – editor of Mergermarket, an Acuris companyOriginally published by Mergermarket and re-published with author permission
October 08, 2021
Logistics & Transportation Review features Cryoport Systems' Chief Operating Officer, Phil Wilson, on a critical and transparent conversation of technology changes coming up on active shipment...
August 17, 2021
Authority Magazine interviews Mark Sawicki, CEO of Cryoport Systems, on his expertise in the science, pharmaceutical and healthcare industry. Sawicki takes on his perspective of the current state of...
April 21, 2021
With the growing market of cell and gene therapy manufacturing, Cryoport's scalability in providing storage and logistics capabilities for these life-saving therapies are now more important than ever.
March 04, 2021
While the COVID-19 vaccine rollouts are excellent news, they will impact the pharma and biopharma supply chain. Cryoport Systems CEO Mark Sawicki outlines what to expect the rest of the year in a new
January 29, 2021
While the pandemic continues to disrupt many industries, including regenerative medicine, it’s not all bad news -- in fact, there are likely some bright spots ahead for the industry this year.
In an
December 03, 2020
Jerrell Shelton, Chief Executive Officer of Cryoport, Inc. recently participated in a live interview on Bloomberg, discussing the complexities and challenges of logistic vaccine distribution, as well...
December 02, 2020
By Joseph Harvey – editor of IHS Markit Animal Health (formerly Animal Pharm)Originally published by IHS Markit Animal Health and re-published with author permission
October 14, 2020
Mark Sawicki, Chief Executive Officer of Cryoport Systems, in collaboration with our strategic partners, Lonza and Vineti, published a new white paper featured in the peer-reviewed journal ...
September 30, 2020
The much-anticipated ISO 21973:2020 has arrived, supplying a set of guidelines and best practices for the transportation of cell and gene therapies. Cryoport’s experts played a role in developing...
July 17, 2020
The last few months have been unprecedented in world history. The pandemic that is gripping the world has spared no country, culture or corner, and it has highlighted the gaps in many companies’...
June 23, 2020
A new Contract Pharma article is all about Cryoport!
January 03, 2020
Commercial Officer Mark Sawicki brings more than a sales background to the company: He also holds a Ph.D. in biochemistry and has a distinguished career in global biopharmaceutical development.
...
December 04, 2019
A new article for Pharma Manufacturing breaks down the technology innovations that are changing cold chain logistics.
November 12, 2019
Cryoport is expanding its impact on regenerative medicine development and distribution via a new partnership with Lonza.
October 15, 2019
“The past year has seen Cryoport establish multiple collaborations and expansions of its offering,” says a new article in BioPharma-Reporter, “due to the booming cell and gene therapy space and the...
September 24, 2019
With just a handful of cell and gene therapies currently on the market, we’ve only seen the tip of the iceberg.
That’s how Cryoport’s Executive Director of Business Development, Ryan Carpentier,...
September 10, 2019
In a new article for Contract Pharma, Cryoport Executive Director of Business Development Ryan Carpentier explains the exciting new opportunities of CAR T-cell immunotherapy, which enables a...
September 10, 2019
New articles in Outsourcing Pharma and Pharmaceutical Commerce highlight the exciting benefits of the recently announced partnership between Cryoport and Vineti.
Americas • EMEA • APAC
Sales • +1 949.232.1900 | Support • +1 949.470.2300
©2022 Cryoport Systems, LLC. All rights reserved.
A Leap Forward in Standardizing the Regenerative Medicine Supply Chain – What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC
